IMPACT BIOMEDICAL INC (IBO) Stock Price & Overview

NYSEARCA:IBO • US45259L2051

Current stock price

0.5748 USD
+0.01 (+1.79%)
At close:
0.5355 USD
-0.04 (-6.84%)
After Hours:

The current stock price of IBO is 0.5748 USD. Today IBO is up by 1.79%. In the past month the price increased by 32.05%.

IBO Key Statistics

52-Week Range0.3621 - 1.95
Current IBO stock price positioned within its 52-week range.
1-Month Range0.4 - 0.83
Current IBO stock price positioned within its 1-month range.
Market Cap
61.975M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.58
Dividend Yield
N/A

IBO Stock Performance

Today
+1.79%
1 Week
-26.31%
1 Month
+32.05%
3 Months
+15.38%
Longer-term
6 Months -12.62%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

IBO Stock Chart

IMPACT BIOMEDICAL INC / IBO Daily stock chart

IBO Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to IBO.


Chartmill TA Rating
Chartmill Setup Rating

IBO Earnings

Next Earnings DateN/A
Last Earnings DateN/A
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

IBO Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

IBO Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

IBO Financial Highlights

Over the last trailing twelve months IBO reported a non-GAAP Earnings per Share(EPS) of -3.58. The EPS decreased by -509.26% compared to the year before.


Income Statements
Revenue(TTM)7.00K
Net Income(TTM)-38.47M
Industry RankSector Rank
PM (TTM) N/A
ROA -201.86%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-1423.03%
Sales Q2Q%N/A
EPS 1Y (TTM)-509.26%
Revenue 1Y (TTM)N/A

IBO Ownership

Ownership
Inst Owners1.38%
Shares107.82M
Float14.39M
Ins Owners0.43%
Short Float %1.36%
Short Ratio0.03

About IBO

Company Profile

IBO logo image Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.

Company Info

IPO: 2024-09-16

IMPACT BIOMEDICAL INC

1400 Broadfield Blvd., Suite 130

Houston TEXAS US

Employees: 2

IBO Company Website

IBO Investor Relations

Phone: 15852321500

IMPACT BIOMEDICAL INC / IBO FAQ

What does IMPACT BIOMEDICAL INC do?

Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.


What is the current price of IBO stock?

The current stock price of IBO is 0.5748 USD. The price increased by 1.79% in the last trading session.


Does IBO stock pay dividends?

IBO does not pay a dividend.


What is the ChartMill rating of IMPACT BIOMEDICAL INC stock?

IBO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is the market capitalization of IBO stock?

IMPACT BIOMEDICAL INC (IBO) has a market capitalization of 61.97M USD. This makes IBO a Micro Cap stock.